Hims & Hers subscribers in Q2
Short Answer
Both the model and the market expect Hims & Hers subscribers to be above 2.6 million in Q2 2026. No actionable edge is seen.
1. Executive Verdict
- Management expects over 100,000 new weight loss subscribers monthly in Q2.
- Management guidance implies Q2 subscriber increase of at least 300,000.
- The company reported 2.584 million subscribers at the end of Q1 2026.
- Alternative data points to re-accelerated subscriber growth for Q2 2026.
- GLP-1 expansion and Novo Nordisk partnership drive substantial subscriber growth.
- Q2 2026 financial results are scheduled for reporting around August 3, 2026.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Above 2.72 million | 82.0% | 79.7% | Management expects over 300,000 new Q2 subscribers, largely from weight loss additions. |
| Above 2.62 million | 97.0% | 96.5% | Robust alternative data and management guidance point to significant Q2 subscriber growth. |
| Above 2.68 million | 84.0% | 81.9% | Management guides for significant monthly weight loss subscriber additions and accelerated overall growth. |
| Above 2.7 million | 83.0% | 80.8% | Strong projected growth from weight loss subscribers increases the likelihood of exceeding this threshold. |
| Above 2.66 million | 86.0% | 84.1% | Q2 subscriber figures are expected to show strong upside due to alternative data and guidance. |
Current Context
Hims & Hers reported nearly 2.6 million subscribers in Q1 2026. The company reached this subscriber count as of Q1 2026, representing a 9% year-over-year increase [^][^][^][^]. Hims & Hers expects to report its Q2 2026 financial results in early August 2026, with estimates for the release date ranging from August 3 to August 10, 2026 [^][^][^][^][^].
Q2 saw strategic initiatives and raised full-year revenue guidance. Key developments for Hims & Hers in Q2 2026 included a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications (Wegovy and Ozempic) [^][^][^][^]. The company also acquired Eucalyptus to expand its international footprint [^][^][^][^]. Management has since raised its full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion, with Q2 revenue projected between $680 million and $700 million [^][^][^].
Market sentiment in June remains volatile regarding execution and policy. This sentiment in June 2026 was influenced by execution concerns regarding the transition to branded GLP-1 drugs [^][^]. Recent insider selling also played a role, alongside potential long-term tailwinds from employers dropping coverage of weight-loss drugs [^][^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This market has exhibited no price movement since its inception. The probability has remained fixed at 94.0% across all 51 recorded data points, indicating a static and unwavering market expectation. There have been no price spikes or drops to analyze, as the market has been completely inactive. This pricing suggests a high degree of confidence that Hims & Hers will report Q2 2026 subscriber numbers at or above the 2,600,000 threshold specified in the contract.
The complete absence of trading volume, with zero contracts exchanged, points to an illiquid market where the initial price has not been tested. This lack of activity suggests that either the market consensus is so strong that no participants are willing to challenge the 94.0% probability, or the market has not attracted any participants at all. Without trading, there is no demonstrated market conviction beyond the initial pricing assessment. Consequently, technical concepts such as support and resistance levels are not applicable.
Market sentiment, as reflected by the static 94.0% price, is overwhelmingly positive regarding the company's ability to meet its subscriber target. This sentiment is likely anchored to the Q1 2026 financial results, where Hims & Hers reported nearly 2.6 million subscribers, representing 9% year-over-year growth. The market appears to be pricing in continued stability or marginal growth from the Q1 figures, viewing the 2.6 million subscriber level as a secure floor for the upcoming Q2 report.
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
📉 June 25, 2026: 11.0pp drop
Price decreased from 72.0% to 61.0%
Outcome: Above 2.76 million
What happened: The primary driver of the 11.0 percentage point drop in the "Hims & Hers subscribers in Q2" prediction market on June 25, 2026, appears to be the broader market reaction to Hims & Hers (HIMS) stock. On this date, HIMS stock declined 6%, primarily due to executive insider selling and investor profit-taking following a recent rally [^][^][^][^]. This market activity likely signaled reduced investor confidence in achieving aggressive Q2 subscriber targets, such as exceeding 2.76 million subscribers from the Q1 2026 baseline of 2.58 million [^][^][^][^][^][^]. Social media was not a primary driver, contributing accelerant, or significant factor, as no relevant social media activity was found.
4. Market Data
Contract Snapshot
This market resolves "Yes" if Hims & Hers Health Inc. reports more than 2,760,000 subscribers for Q2 2026, and "No" if the reported number is 2,760,000 or fewer. The outcome is officially verified by Fiscal.ai. Trading opened on May 21, 2026, and will close either upon the Q2 2026 subscriber report or by September 2, 2026, at 4:00 PM EDT, with payouts expected 30 minutes after closing; insider trading is prohibited.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Above 2.62 million | $0.96 | $0.09 | 97% |
| Above 2.64 million | $0.95 | $0.13 | 95% |
| Above 2.6 million | $0.99 | $0.06 | 94% |
| Above 2.66 million | $0.91 | $0.17 | 86% |
| Above 2.68 million | $0.89 | $0.16 | 84% |
| Above 2.7 million | $0.82 | $0.26 | 83% |
| Above 2.72 million | $0.78 | $0.30 | 82% |
| Above 2.76 million | $0.52 | $0.56 | 61% |
| Above 2.80 million | $0.40 | $0.68 | 59% |
| Above 2.84 million | $0.24 | $0.84 | 51% |
| Above 2.88 million | $0.15 | $0.92 | 22% |
| Above 2.92 million | $0.11 | $0.98 | 15% |
| Above 2.96 million | $0.09 | $0.99 | 14% |
| Above 3.00 million | $0.07 | $0.98 | 9% |
| Above 3.04 million | $0.05 | $0.98 | 7% |
Market Discussion
Hims & Hers reported approximately 2.584 million subscribers as of March 31, 2026, reflecting a 9% year-over-year increase for Q1 2026 [^][^][^]. For the second quarter of 2026, the company issued guidance expecting revenue between $680 million and $700 million and Adjusted EBITDA between $35 million and $55 million [^][^]. Social media and trader discussions in mid-2026 indicate mixed investor sentiment, with excitement over growth initiatives like GLP-1 expansion and the Eucalyptus acquisition contrasted by caution regarding regulatory risks, insider share sales, and high valuation multiples [^][^][^][^][^][^].
5. How will the Hims & Hers partnership with Novo Nordisk to distribute GLP-1 drugs impact subscriber acquisition in Q2 2026?
| Q1 2026 Subscribers | Nearly 2.6 million [^] |
|---|---|
| GLP-1 Strategy Change | Pivot to FDA-approved branded GLP-1s announced in March 2026 [^][^] |
| Stock Price Increase | Approx. 41% (30 days leading up to late June 2026) [^][^] |
Hims & Hers pivoted to FDA-approved GLP-1 drugs via Novo Nordisk partnership. In March 2026, Hims & Hers announced a strategic shift to discontinue advertising compounded GLP-1 medications and instead collaborate with Novo Nordisk to offer access to FDA-approved branded options like Wegovy and Ozempic [^][^]. As of late June 2026, official subscriber counts for Q2 2026 have not been finalized, making it impossible to definitively state the precise impact on net subscriber acquisition rates [^]. Analysts are closely observing how this strategic change will affect acquisition rates, particularly considering potential price sensitivity among consumers and the logistical aspects of this transition [^].
Despite Q1 revenue miss, the company shows strong Q2 market momentum. Hims & Hers experienced a miss in Q1 2026 revenue estimates, a performance partly attributed to its ongoing business model transition [^]. However, the company subsequently raised its revenue forecast in May 2026, signaling an optimistic outlook for its new GLP-1 strategy [^]. Management has expressed strong confidence in the potential for future growth [^]. The company reported nearly 2.6 million subscribers at the close of Q1 2026 [^]. This partnership and broader GLP-1 expansion, combined with the acquisition of Eucalyptus, have collectively generated significant positive market momentum for Hims & Hers during Q2 2026 [^][^], with the stock price climbing approximately 41% in the 30 days leading up to late June 2026 [^][^].
6. What are the consensus Wall Street analyst estimates for Hims & Hers' subscriber count for Q2 2026?
| Q1 2026 Subscribers | 2.58 million (Q1 2026 earnings report) [^] |
|---|---|
| Q2 2026 Subscriber Expectation | 2.96 million (Prediction Markets, late May 2026) [^] |
| Q2 2026 Revenue Guidance | $680 million to $700 million (Company guidance) [^] |
Wall Street consensus for Hims & Hers' Q2 2026 subscriber count is unavailable. Consensus Wall Street analyst estimates for Hims & Hers' subscriber count for the second quarter of 2026 are not publicly provided. The company reported approximately 2.58 million subscribers as of its first-quarter 2026 earnings report and did not offer specific subscriber count guidance for the upcoming quarter [^].
Prediction markets provide insights into Q2 2026 subscriber expectations. Despite the absence of company-provided subscriber guidance, prediction markets on platforms such as Kalshi and Coinbase indicated a median expectation centered around 2.96 million subscribers for Hims & Hers in Q2 2026, as of late May 2026 [^]. These markets featured various strike prices, including 2.88M, 2.92M, 2.96M, 3.00M, and 3.04M [^]. While specific subscriber counts were not guided, Hims & Hers did provide revenue guidance for Q2 2026, projecting figures between $680 million and $700 million [^].
7. How does Hims & Hers' projected Q2 2026 subscriber growth rate compare to key digital health competitor Ro?
| Hims & Hers Q1 2026 Subscribers | nearly 2.6 million [^][^][^][^] |
|---|---|
| Ro Estimated Active Subscribers (2026) | approximately 900,000 [^] |
| Hims & Hers Q1 2026 YoY Growth | 9% [^][^][^][^][^][^] |
Hims & Hers projects accelerated subscriber growth, driven by strategic initiatives. The company reported nearly 2.6 million subscribers as of Q1 2026 and anticipates an acceleration of its Q1 2026 year-over-year growth rate of 9% [^][^][^][^][^][^]. This projected acceleration is significantly bolstered by the company's strategic pivot into branded GLP-1 products and an ongoing partnership with Novo Nordisk, which management expects will continue to expand their consumer reach [^][^][^]. Hims & Hers employs an aggressive paid-acquisition, high-volume growth strategy and has an approximate churn rate of 4.8% with an average subscriber tenure of 9–11 months [^][^].
Competitor Ro operates a clinical-first model with lower churn and longer tenure. Private competitor Ro is estimated to have approximately 900,000 active subscribers as of 2026 [^]. Ro operates with a distinct, clinical-first model characterized by a lower churn rate, around 3.6%, and a longer average subscriber tenure of approximately 14 months [^]. Ro focuses on clinical outcomes and higher organic/referral traffic [^][^].
Specific Q2 2026 subscriber growth rates for Ro are unavailable. While Hims & Hers explicitly expects its subscriber growth to accelerate, the available facts do not provide a specific projected Q2 2026 subscriber growth rate for Ro [^]. The contrasting strategies employed by these companies highlight different approaches to market penetration and subscriber retention within the digital health sector.
8. What leading indicators for subscriber growth can be found in alternative data for Hims & Hers from Q2 2026?
| Weekly Transactions & Customers | All-time highs by June 2026 [^][^][^] |
|---|---|
| Hers Web Traffic Growth | 65% year-over-year increase by mid-June 2026 [^][^] |
| Open Roles | Decreased from over 100 in February 2026 to 62-66 by June 2026 [^][^] |
Hims & Hers shows strong alternative data pointing to subscriber growth re-acceleration. Alternative data for Hims & Hers in Q2 2026 indicates a re-acceleration in subscriber growth, evidenced by record-high weekly transactions and customer counts observed by June 2026 [^][^][^]. Additionally, web traffic for both Hims and Hers reached all-time highs in May 2026, with Hers specifically demonstrating a 65% year-over-year increase on a trailing 4-week basis as of mid-June 2026 [^][^]. Further evidence supporting this trend includes strong app store performance, as Hers consistently outranked competitors in the iOS App Store throughout Q2 2026, and positive year-over-year credit card sales data for three consecutive weeks in June 2026 [^][^][^].
Hims & Hers' hiring pace suggests operational optimization over aggressive expansion. Conversely, the company's hiring activity indicates a cooling trend, with open roles decreasing from over 100 in February 2026 to between 62 and 66 by June 2026 [^][^]. This reduction in hiring suggests a focus on optimizing existing operations rather than pursuing aggressive expansion, presenting a contrasting indicator amid otherwise positive signals for subscriber growth.
9. Based on the company's Q2 2026 revenue guidance of $680-$700 million, what is the implied range for subscriber growth?
| Q2 2026 Revenue Guidance | $680 million to $700 million [^][^][^] |
|---|---|
| Subscribers (Q1 2026) | Nearly 2.6 million [^] |
| Monthly Weight Loss Subscribers Added | More than 100,000 [^] |
Calculating implied subscriber growth for Q2 2026 is currently not possible. The available research does not provide sufficient data to determine an implied range for subscriber growth based on Hims & Hers' Q2 2026 revenue guidance. Critical information, specifically the average revenue per subscriber, is absent from the provided facts, which is essential for deriving subscriber growth from revenue projections.
Management expects significant monthly additions of weight loss subscribers. Management indicated an expectation to add over 100,000 new weight loss subscribers per month to the platform [^]. However, official company guidance for Q2 did not include a specific total subscriber count for the end of the quarter, preventing the calculation of an implied subscriber growth range using the provided revenue guidance [^].
10. What Could Change the Odds
Key Catalysts
Hims & Hers is scheduled to report its Q2 2026 financial results on or around August 3, 2026 [^] . Key growth catalysts include the expansion of its GLP-1 weight-loss treatment offerings, a new partnership with Novo Nordisk, and the acquisition of Eucalyptus to expand international footprint [^]. As of the end of Q1 2026, the company reported approximately 2.584 million subscribers [^][^][^].
Key Dates & Catalysts
- Expiration: September 02, 2026
- Closes: September 02, 2026
11. Decision-Flipping Events
- Trigger: Hims & Hers is scheduled to report its Q2 2026 financial results on or around August 3, 2026 [^] .
- Trigger: Key growth catalysts include the expansion of its GLP-1 weight-loss treatment offerings, a new partnership with Novo Nordisk, and the acquisition of Eucalyptus to expand international footprint [^] .
- Trigger: As of the end of Q1 2026, the company reported approximately 2.584 million subscribers [^] [^] [^] .
- Trigger: Bearish sentiment focuses on high valuation multiples, specifically 44.6x forward P/E, inconsistent profitability, and risks associated with execution in competitive weight-loss markets [^] [^] .
13. Historical Resolutions
Historical Resolutions: 9 markets in this series
Outcomes: 4 resolved YES, 5 resolved NO
Recent resolutions:
- KXHIMS-26MAYSUBS-2800000.0: NO (May 11, 2026)
- KXHIMS-26MAYSUBS-2750000.0: NO (May 11, 2026)
- KXHIMS-26MAYSUBS-2700000.0: NO (May 11, 2026)
- KXHIMS-26MAYSUBS-2650000.0: NO (May 11, 2026)
- KXHIMS-26MAYSUBS-2600000.0: NO (May 11, 2026)
